Talis Biomedical Corporation Stock News

SAN FRANCISCO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Talis Biomedical Corporation (NASDAQ: TLIS) investors with significant losses to submit your losses now . A securities class action has been filed concerning defendants’ representations during Talis’ Feb. 2021 initial public offering.

NEW YORK, Feb. 13, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Meta Materials, Inc. (NASDAQ: MMAT ), Bright Health Group, Inc. (NYSE: BHG ), First Solar, Inc. (NASDAQ: FSLR ), and Talis Biomedical Corporation (NASDAQ: TLIS ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Meta Materials, Inc. (NASDAQ: MMAT ) Class Period: September 21, 2020 December 14, 2021 Lead Plaintiff Deadline: March 4, 2022 According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose: (1) the business combination of Torchlight Energy Resources, Inc. and Metamaterial Inc. would result in an SEC investigation and subpoena in the matter captioned In the Matter of Torchlight Energy Resources, Inc.; (2) the Company has materially overstated its business connections and dealings; (3) the Company has materially overstated its ability to produce and commercialize its products; (4) the Company has materially overstated its products'' novelty and capabilities; (5) the Company''s products did not have the potential to be disruptive because, among other things, the Company priced its products too high; and (6) as a result, Defendants'' public statements were materially false and/or misleading at all relevant times.

ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Talis Biomedical Corporation Investors with Losses in Excess of $100K TLIS

RADNOR, Pa. , Feb. 11, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed against Talis Biomedical Corporation ("Talis") (NASDAQ: TLIS ). The action charges Talis with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company''s business, operations, and prospects. As a result of Talis'' materially misleading statements to the public, Talis investors have suffered significant losses. Kessler Topaz is one of the world''s foremost advocates in protecting the public against corporate fraud and other wrongdoing. Our securities fraud litigators are regularly recognized as leaders in the field individually and our firm is both feared and respected among the defense bar and the insurance bar. We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent. CANNOT VIEW THIS VIDEO?

NEW YORK, Feb. 9, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice on behalf of shareholders of Talis Biomedical Corporation. Shareholders who purchased shares of TLIS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff…

NEW YORK, Feb. 8, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Talis Biomedical Corporation (NASDAQ: TLIS) alleging that the Company violated federal securities laws. This lawsuit is on behalf of persons and…

SAN FRANCISCO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Talis Biomedical Corporation (NASDAQ: TLIS) investors with significant losses to submit your losses now . A securities class action has been filed concerning defendants representations during Talis Feb. 2021 initial public offering.

SAN FRANCISCO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Talis Biomedical Corporation (NASDAQ: TLIS ) investors with significant losses to submit your losses now . A securities class action has been filed concerning defendants'' representations during Talis'' Feb. 2021 initial public offering. Class Period: Feb. 8, 2021 Jan. 7, 2022 Lead Plaintiff Deadline: Mar. 8, 2022 Visit: www.hbsslaw.com/investor-fraud/TLIS Contact An Attorney Now: [email protected] 844-916-0895 Talis Biomedical Corporation (TLIS) Securities Class Action: Talis touted in its IPO documents that it submitted an application for emergency use authorization ("EUA") to the FDA for its Talis One COVID-19 test in Jan. 2021. The company said it assessed the performance of the Talis One platform comparing nasal specimens with tests conducted in a central lab using the Center for Disease Control and Prevention assay, the test data used to assess the test exactly matched Full story available on Benzinga.com

RADNOR, Pa., Feb. 07, 2022 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Talis Biomedical Corporation (Talis) ( NASDAQ: TLIS ). The action charges Talis with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the companys business, operations, and prospects. As a result of Talis materially misleading statements to the public, Talis investors have suffered significant losses.

ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Talis Biomedical Corporation Investors with Losses in Excess of $100K – TLIS

NEW YORK , Jan. 31, 2022 /PRNewswire/ -- Attention Talis Biomedical Corporation ("Talis") (NASDAQ: TLIS ) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of TLIS investors. This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Talis common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company''s February 2021 initial public offering. If you suffered a loss on your investment in Talis, contact us about potential recovery by using the link below. There is no cost or Full story available on Benzinga.com

SAN FRANCISCO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Talis Biomedical Corporation (NASDAQ: TLIS) investors with significant losses to submit your losses now . A securities class action has been filed concerning defendants representations during Talis Feb. 2021 initial public offering.

Talis Biomedical Corp (TLIS) shares closed today at 1.9% above its 52 week low of $3.11, giving the company a market cap of $85M. The stock is currently down 19.2% year-to-date, down 88.3% over the past 12 months, and down 88.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 57.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 2656.4% The company's stock price performance over the past 12 months lags the peer average by 932.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.